AIDS 2020: Virtual – Recap
AIDS 2020: Virtual – Rapid Audio Recap

Released: August 14, 2020

Expiration: August 13, 2021

Chloe Orkin
Chloe Orkin, MBChB, FRCP, MD

Activity

Progress
1
Course Completed

In this episode, Dr. Orkin discusses results from key studies reported at AIDS 2020: Virtual, with new data on the following hot topics: current ART in principal populations, including older patients and women who become pregnant; metabolic outcomes during ART; HIV and COVID-19; investigational ART strategies; and HIV prevention. The overview includes:

  • The ADVANCE trial comparing initial ART with DTG plus FTC/TAF, DTG plus FTC/TDF, or EFV/FTC/TDF
  • A pooled analysis of randomized trials evaluating a switch to BIC/FTC/TAF in patients 65 years of age or older with virologic suppression on their current ART
  • A Kaiser Permanente study of BMI changes over time following ART initiation
  • An analysis of the longitudinal prospective OPERA cohort that assessed weight change with switch from TDF to TAF
  • Metabolic changes with switch from 3- or 4-drug TAF-based ART to 2-drug DTG/3TC in the TANGO study
  • Updated findings from the Tsepamo birth surveillance study in Botswana evaluating the prevalence of neural tube defects by antiretroviral exposure during conception/pregnancy
  • A retrospective study of COVID-19 in people with HIV presenting at 5 New York City Emergency Departments from March 2 to April 15, 2020
  • An analysis of protocol-defined virologic failure in the P011 study comparing islatravir plus DOR vs DOR/3TC/TDF in treatment-naive adults
  • A study evaluating the lenacapavir pharmacokinetic profile
  • Results from the HPTN 083 trial investigating the efficacy and safety of long-acting injectable cabotegravir vs daily oral TDF/FTC for PrEP in MSM and TGW

Content based on a CME program supported by independent educational grants from Gilead Sciences, Merck Sharp & Dohme Corp., and ViiV Healthcare.

Link to full program: https://www.clinicaloptions.com/hiv/conference-coverage/aids-2020